Autologous melanoma tumor cells

Autologous melanoma tumor cells serve as a personalized therapeutic target characterized by a unique profile of somatic mutations known as neoantigens (Sahin et al., 2017, Nature). Unlike conventional molecular targets, this target is a heterogeneous cell population that is recognized by the patient's own immune system, particularly by tumor-infiltrating lymphocytes (TILs) (Rosenberg & Restifo, 2015, Science). The biological function of this target in a therapeutic context is to act as the substrate for immune-mediated destruction, where T-cells identify specific peptide-HLA complexes on the tumor surface (Ott et al., 2017, Nature). This target is central to the treatment of advanced melanoma, where drugs like lifileucel (Amtagvi) utilize the patient's own TILs to recognize and kill these specific cells (FDA, 2024). Additionally, personalized mRNA vaccines like mRNA-4157 are designed to train the immune system to target these unique tumor cells by encoding for the specific neoantigens they express (Weber et al., 2024, The Lancet). Therapeutic challenges include the high degree of tumor heterogeneity and the potential for immune escape through the downregulation of antigen presentation machinery (Zaretsky et al., 2016, NEJM).

Other names

Patient-specific melanoma cellsAutologous tumor cellsNeoantigen-expressing melanoma cellsPatient-derived melanoma cells

Recognition of patient-specific neoantigens by tumor-infiltrating lymphocytes (TILs) or vaccine-induced T-cells to trigger cell-mediated cytotoxicity and tumor lysis.